Trial Profile
A Phase 2, Randomized, Controlled, Observer-Blinded Study to Describe the Immunogenicity, Safety, and Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs PF 5212366 (Primary) ; Hepatitis A vaccine inactivated
- Indications Hepatitis A; Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 23 Apr 2018 Pfizer received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years, based on data from this study and other completed phase 2 studies in this investigational age group, according to Pfizer media release.
- 06 Apr 2017 This trial has been completed in Finland (End date:2017-03-01) as per European Clinical Trials Database record.
- 05 Apr 2017 Status changed from active, no longer recruiting to completed.